PD-L1 deletion or blockade intrinsically reduces macrophage CD80 levels
Frontiers in Oncology · 30.10.2026 · 16
DOI: 10.3389/fonc.2026.1917545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 30.10.2026. Verfasst von Trinity Waddell und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Mayo Clinic, Phoenix, AZ, United States. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Introduction
Macrophages in the tumor microenvironment are known to upregulate PD-L1 expression, thereby suppressing T cells through PD-1 ligation. However, the manner in which PD-L1 expression intrinsically impacts macrophages and their immunomodulatory phenotype is less clear. Clarifying this knowledge gap may provide further insight into macrophage function within the tumor microenvironment.
Methods
To characterize the macrophage intrinsic role of PD-L1, we used complementary genetic and pharmacological approaches by analyzing primary murine bone marrow-derived macrophages (BMDMs) with complete genetic PDL1 deletion and wildtype BMDMs treated with anti-PD-L1 blocking antibodies. Macrophages were evaluated in vitro across naïve, pro-inflammatory, and tumor conditioned polarization states.
Results
Unlike prior reports, neither genetic deletion nor antibody blockade dramatically altered the expression of macrophage polarization markers or in vitro phagocytic capacity. However, both conditions consistently and robustly reduced surface levels of a costimulatory molecule, CD80. Reduced CD80 levels prompted further analysis of T cell interacting and antigen presentation associated surface proteins, in which we revealed disparate effects of expression in response to PD-L1 genetic deletion and antibody blockade.
Discussion
Collectively, these findings suggest that loss of macrophage PD-L1 reduces CD80 expression and regulates immunoregulatory surface protein expression in vitro .
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, Mayo Clinic, Phoenix, AZ, United States.
- Department of Biochemistry, University of Utah, Salt Lake City, UT, United States.
- Department of Immunology, Mayo Clinic, Rochester, MN, United States.
- Department of Cancer Biology, Mayo Clinic, Phoenix, AZ, United States.
Förderung
- NIA NIH HHS
- NCI NIH HHS
Zitieren
APA
Waddell, T., Dong, H., Roh-Johnson, M., & Lancaster, J. N. (2026). PD-L1 deletion or blockade intrinsically reduces macrophage CD80 levels. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1917545
Vancouver
Waddell T, Dong H, Roh-Johnson M, Lancaster JN. PD-L1 deletion or blockade intrinsically reduces macrophage CD80 levels. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1917545
BibTeX
@article{Waddell2026,
author = {Waddell, Trinity and Dong, Haidong and Roh-Johnson, Minna and Lancaster, Jessica N},
title = {PD-L1 deletion or blockade intrinsically reduces macrophage CD80 levels},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1917545}
}
EUVIMED